Source comparison
Kisspeptin Dosage Protocols: Research vs Clinical Applications Comparison
Reproductive Endocrinology Research 0.01–10 nmol/kg bolus or 0.1–4.0 nmol/kg/hr infusion IV or SC Single bolus or continuous infusion 1–8 hours LH pulsatility, FSH response, GnRH neuron activation Use molar dosing (nmol/kg) and adjust for administration route
This comparison does not assign a generated winner or score.
- Reproductive Endocrinology Research
- 0.01–10 nmol/kg bolus or 0.1–4.0 nmol/kg/hr infusion
- IV or SC
- Single bolus or continuous infusion 1–8 hours
- LH pulsatility, FSH response, GnRH neuron activation
- Use molar dosing (nmol/kg) and adjust for administration route bioavailability. SC requires 1.3–1.5× the IV dose for equivalent plasma levels
- Ovulation Induction Studies
- 6.4–12.8 nmol/kg SC
- Subcutaneous
- Twice daily for 2–4 weeks
- Follicular maturation, ovulation timing, oocyte retrieval yield
- Higher doses and chronic administration protocols require cumulative dose tracking and monitoring for receptor desensitisation
- Male Hypogonadism Research
- 1.0 nmol/kg/hr IV infusion
- Intravenous
- Continuous 8–24 hours
- Testosterone response, LH secretion patterns, testicular volume changes
- Long infusions demand low-protein-binding tubing and pre-saturation to prevent peptide adhesion losses of 10–20%
- Kisspeptin Analog Screening
- 0.001–1.0 nmol/kg wide dose-ranging
- IV bolus
- Single administration
- Receptor binding affinity, duration of LH elevation, half-life estimation
- Start at sub-threshold doses and escalate. Analogs may have 10–100× potency variation from native kisspeptin-10
- Body Weight vs Fixed Dose Studies
- Fixed 1–10 nmol vs weight-adjusted 0.1–1.0 nmol/kg
- Variable
- Dose-response curve characterisation
- Weight-adjusted dosing accounts for distribution volume differences; fixed dosing simplifies comparison but introduces variability in plasma concentration